[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].
Japanese guideline for the diagnosis and management of bronchial asthma was initially reported in 1998 and revised in 2000. This guideline was based on two former guidelines which were made by Japanese Allergology Society in 1993 and NIH.NHLBI in 1995 (GINA). New version of this guideline in 2000 pointed that the efficacy and adverse reaction of leukotriene receptor antagonists, the effectiveness of new inhaled corticosteroid (fluticasone propionate), and transdermal administration of beta-2 stimulant (tulobuterol hydrochloride). The precise evaluation of this guideline in terms of propriety, reliability, applicability and so on was not performed.
Numao
T
T
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine.
Fukuda
T
T
D000279:Administration, Cutaneous; D000280:Administration, Inhalation; D000628:Aminophylline / Q000008:administration & dosage / Q000009:adverse effects; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control; D019317:Evidence-Based Medicine; D000068298:Fluticasone; D006801:Humans; D007262:Infusions, Intravenous; D007564:Japan; D020024:Leukotriene Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D015397:Program Evaluation; D013726:Terbutaline / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000730:Androstadienes; D020024:Leukotriene Antagonists; D000628:Aminophylline; C010809:tulobuterol; D000068298:Fluticasone; D013726:Terbutaline